Bayesian Health vs Healthplus.ai
Both predict that a patient is heading for trouble and they define the target differently, which is why the comparison is useful rather than competitive. Healthplus.ai predicts postoperative bacterial infection specifically, is certified in Europe as software as a medical device, and carries the most methodologically complete published evaluation in this category, with calibration treated as the central problem rather than an afterthought. Bayesian Health detects general deterioration and sepsis across the inpatient population, with three large prospective multi site studies behind it and clinician response engineered into the deployment. The calibration point is the one worth taking from this pair regardless of which vendor you buy: a model that discriminates well in one hospital will still misestimate absolute risk in another, and almost nobody in this category is asked to demonstrate local calibration before go live.
- The published evaluation is the most methodologically complete in this category, appearing in a regional journal of a major medical publisher rather than in vendor material.
- Calibration is treated as the central problem rather than discrimination, which is the right emphasis for a risk model that will move between institutions with different baseline rates.
- The model class is named plainly and the certification carries an adjunctive constraint, so what the tool may and may not be used for is written down rather than implied.
- The evidence is prospective, multi site and conducted with a major academic health system, which is a different and harder study design than retrospective validation.
- It is deployed in United States hospitals and configured across several risk questions rather than one condition, so a single integration serves more than one programme.
- Clinician response was engineered into the deployment rather than assumed, which is what separates a model that fires from a model that changes outcomes.
Side by Side
| Axis | B Bayesian Health |
H Healthplus.ai |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Inpatient Deterioration & Risk Monitoring page.
The scopes differ enough that these are not substitutes: one predicts postoperative bacterial infection in surgical patients, the other detects general deterioration and sepsis across inpatients, so a hospital could reasonably run both. Healthplus.ai holds European certification and states it is pursuing United States authorisation, which means it is not currently available for clinical use in the United States; check status before evaluating.
Neither vendor publishes a security attestation, business associate terms, retention or training use position, and neither publishes pricing. Both should be asked for alert burden per patient day and for local calibration performance before deployment, since a model calibrated elsewhere will misestimate risk in your population.